Moleculin Biotech (MBRX) Reports Q1 Result
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update
May 12, 2022 8:35 AM EDTPositive advancements, encouraging preclinical and clinical data, and development activity in all three core technologies
Multiple key clinical and regulatory milestones expected throughout 2022 Â
Company has sufficient capital to fund operations into 2024 Â
HOUSTON, May 12, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended March 31, 2022. The Company also provided an update on its portfolio of oncology drug... More
